What the buyer wrote
CGT Catapult has entered into a strategic collaboration agreement with Ena Biologics for the development and manufacture of biologics. This collaboration for the Braintree site requires significant qualification and validation of systems, equipment, and processes. The objective of this collaboration is to launch a commercial GLP-1 Biosimilar into the European market in 2029. Commercial medicinal products require full end to end qualification and validation of all direct impact systems, equipment, and processes ensuring documented and objective evidence that they meet their intended use and ensure all critical process parameters and critical quality attributes are documented and validated. …
Bid for this and lost? There is a short window in which the decision can be questioned.
Awarded to
Details
- What the buyer calls it
- Computer Systems Validation Contractor
- How they are buying
- The buyer did not say
- Work starts
- 30 Sep 2026
- Work ends
- 2 Mar 2027
- Where
- in London
Who the buyer named
The buyer published a contact address on this notice.